

Claudia Arenaccio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8759129/publications.pdf>

Version: 2024-02-01

25
papers

765
citations

566801

15
h-index

642321

23
g-index

25
all docs

25
docs citations

25
times ranked

1075
citing authors

#	ARTICLE	IF	CITATIONS
1	HIV-1 Nef Protein Affects Cytokine and Extracellular Vesicles Production in the GEN2.2 Plasmacytoid Dendritic Cell Line. <i>Viruses</i> , 2022, 14, 74.	1.5	0
2	Extracellular vesicle-mediated intercellular communication in HIV-1 infection and its role in the reservoir maintenance. <i>Cytokine and Growth Factor Reviews</i> , 2020, 51, 40-48.	3.2	6
3	N-Terminal Fatty Acids of NEFMUT Are Required for the CD8+ T-Cell Immunogenicity of In Vivo Engineered Extracellular Vesicles. <i>Vaccines</i> , 2020, 8, 243.	2.1	8
4	Tumor cells endowed with professional antigen-presenting cell functions prime PBLs to generate antitumor CTLs. <i>Journal of Molecular Medicine</i> , 2019, 97, 1139-1153.	1.7	4
5	<p>The Intracellular Delivery Of Anti-HPV16 E7 scFvs Through Engineered Extracellular Vesicles Inhibits The Proliferation Of HPV-Infected Cells</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 8755-8768.	3.3	18
6	An Exosome-Based Vaccine Platform Imparts Cytotoxic T Lymphocyte Immunity Against Viral Antigens. <i>Biotechnology Journal</i> , 2018, 13, e1700443.	1.8	77
7	Engineered exosomes emerging from muscle cells break immune tolerance to HER2 in transgenic mice and induce antigen-specific CTLs upon challenge by human dendritic cells. <i>Journal of Molecular Medicine</i> , 2018, 96, 211-221.	1.7	29
8	DNA Vectors Generating Engineered Exosomes Potential CTL Vaccine Candidates Against AIDS, Hepatitis B, and Tumors. <i>Molecular Biotechnology</i> , 2018, 60, 773-782.	1.3	24
9	Exosomes in Therapy: Engineering, Pharmacokinetics and Future Applications. <i>Current Drug Targets</i> , 2018, 20, 87-95.	1.0	34
10	Trans-dissemination of exosomes from HIV-1-infected cells fosters both HIV-1 trans-infection in resting CD4+ T lymphocytes and reactivation of the HIV-1 reservoir. <i>Archives of Virology</i> , 2017, 162, 2565-2577.	0.9	11
11	The Multifaceted Functions of Exosomes in Health and Disease: An Overview. <i>Advances in Experimental Medicine and Biology</i> , 2017, 998, 3-19.	0.8	54
12	Antitumor HPV E7-specific CTL activity elicited by in vivo engineered exosomes produced through DNA inoculation. <i>International Journal of Nanomedicine</i> , 2017, Volume 12, 4579-4591.	3.3	58
13	The CD8+ T Cell-Mediated Immunity Induced by HPV-E6 Uploaded in Engineered Exosomes Is Improved by ISCOMATRIX™ Adjuvant. <i>Vaccines</i> , 2016, 4, 42.	2.1	13
14	Incorporation of Heterologous Proteins in Engineered Exosomes. <i>Methods in Molecular Biology</i> , 2016, 1448, 249-260.	0.4	18
15	Latent HIV-1 is activated by exosomes from cells infected with either replication-competent or defective HIV-1. <i>Retrovirology</i> , 2015, 12, 87.	0.9	77
16	The Contribution of Extracellular Nef to HIV-Induced Pathogenesis. <i>Current Drug Targets</i> , 2015, 17, 46-53.	1.0	16
17	HPV-E7 Delivered by Engineered Exosomes Elicits a Protective CD8+ T Cell-Mediated Immune Response. <i>Viruses</i> , 2015, 7, 1079-1099.	1.5	47
18	miR-146a controls CXCR4 expression in a pathway that involves PLZF and can be used to inhibit HIV-1 infection of CD4+ T lymphocytes. <i>Virology</i> , 2015, 478, 27-38.	1.1	26

#	ARTICLE	IF	CITATIONS
19	Uncovering the role of defective HIV-1 in spreading viral infection. <i>Future Virology</i> , 2015, 10, 371-381.	0.9	1
20	The ADAR1 editing enzyme is encapsidated into HIV-1 virions. <i>Virology</i> , 2015, 485, 475-480.	1.1	12
21	Surface-bound Tat inhibits antigen-specific CD8+ T-cell activation in an integrin-dependent manner. <i>Aids</i> , 2014, 28, 2189-2200.	1.0	24
22	Cell activation and HIV-1 replication in unstimulated CD4+T lymphocytes ingesting exosomes from cells expressing defective HIV-1. <i>Retrovirology</i> , 2014, 11, 46.	0.9	52
23	Exosomes from Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Cells License Quiescent CD4 ⁺ T Lymphocytes To Replicate HIV-1 through a Nef- and ADAM17-Dependent Mechanism. <i>Journal of Virology</i> , 2014, 88, 11529-11539.	1.5	140
24	HIV-1-infected cells transiently express lentiviral RNA shuttled by exosomes. <i>Future Virology</i> , 2014, 9, 111-121.	0.9	0
25	HIV-1 Nef Impairs Key Functional Activities in Human Macrophages through CD36 Downregulation. <i>PLoS ONE</i> , 2014, 9, e93699.	1.1	16